<p>Appendix II: cost calculations</p><p>Cost of treatment and cost of follow-up (year 1 and 2)</p><p>Within the RW observational study, resource use data were drawn from a random subset of 206 individual patients included in this study. Mean costs per patient were calculated for the four most common treatment regimens seen in daily practice: 5-FU/LV, capecitabine, 5-FU/LV with oxaliplatin (FOLFOX) and capecitabine with oxaliplatin (CAPOX). Total costs for individual patients were determined by the identification of resource use and unit costs of the following cost components: inpatient hospital days, intensive care days, outpatient visits, consultations by telephone, daycare treatments, emergency room visits, radiotherapy, surgical procedures, laboratory services, medical imaging services, chemotherapy and concomitant medications. </p><p>Resource use was divided into two time periods, a treatment phase (period 1) and a follow- up phase (Period 2). Period 1 began on day 1 of the first administration of adjuvant chemotherapy. To capture resource use resulting from treatment related toxicity, period 1 ended one month after the last administration of chemotherapy. Period 2 started one month after the last administration of chemotherapy and lasted until disease progression (or end of follow up).(1) Cost in the treatment, follow-up phase (period 1 and 2 Euro 2012) FL only FL + oxaliplatin 5FU/LV Capecitabine FOLFOX CAPOX n = 206 N = 15 N = 89 N = 37 N = 65 Total treatment costs mean € 6,163 € 5,229 € 27,446 € 14,783 SD € 3,076 € 3,356 € 11,938 € 5,944 Total costs of follow-up mean € 3,518 € 4,507 € 5,347 € 3,578 SD € 3,863 € 8,083 € 7,511 € 4,240 Share of regimen within RW population 15% 85% 48% 52%</p><p>Pooled total treatment costs* mean € 5,369 € 20,861 SD € 3,302 € 8,555 Total costs of follow-up mean € 4,293 SD € 6,677 Average Follow-up time 1.8 year</p><p>Average cost of follow-up/ 3-month cycle, during year 1 and 2 mean € 596 SD € 927 * calculated by multiplying costs per regimen by the actual share found in RW practice Resource use & costs year 3 - 5(2) </p><p> unit costs units/3 months costs/cycle</p><p>Laboratory tests € 38 0.50 € 19 Ultrasound liver € 92 0.25 € 23 X-ray of thorax € 55 0.25 € 14 Colonoscopy € 473 0.08 € 39 Monitoring visits € 104 0.50 € 52</p><p>Totals/ 3- month cycle € 147</p><p>Total costs post-relapse (including costs in later treatment lines) in patients receiving FL alone, FL + oxaliplatin or FL + irinotecan as first-line treatment (1) FL FL + FL + alone oxaliplatin irinotecan n = 198 n = 92 n = 26 Total cost post-relapse mean € 20,433 € 29,435 € 41,824 SD € 15,592 € 20,681 € 25,883 Total costs post-relapse over all treatments mean € 24,814 SD € 16,967 Mean survival 466 days </p><p>Mean cost post-relapse/ 3-month cycle € 4,872</p><p>References</p><p>(1) van Gils CWM, Redekop WK, de Groot S, Tan SS, Koopman M, Mol L, et al. Pilot outcomes research: costs and effects of oxaliplatin in stage III and metastatic colorectal cancer. 2010; Available at: http://www.cvz.nl/binaries/live/cvzinternet/hst_content/nl/documenten/rubriek+zorgpakket/imta- onderzoek-dure-geneesmiddelen-1207.pdf. (2) Richtlijnen oncologische zorg, www.oncoline.nl. </p>